ResibufogeninA specific inhibitor of Na+/K+-ATPase

Resibufogenin (CAS 465-39-4)

Resibufogenin | CAS 465-39-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_12, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202788, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 214ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Application: A specific inhibitor of Na+/K+-ATPase
CAS Number: 465-39-4
Purity: ≥98%
Molecular Weight: 384.5
Molecular Formula: C24H32O4
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Resibufogenin is a specific Sodium/Potassium-ATPase Protein ( Na+/K+-ATPase )inhibitor.


References

1. Xie, J.T., et al. 2000. Am. J. Chin. Med. 28: 187-196. PMID: 10999437
2. Vu, H., et al. 2006. Exp. Biol. Med. 231: 215-220. PMID: 16446498

Physical State :
Solid
Derived From :
Bufonis venom
Solubility :
Soluble in chloroform, and water (partly).
Storage :
Store at 4° C
Melting Point :
113-140° C
Boiling Point :
554.93° C at 760 mmHg (Predicted)
Density :
1.25 g/cm3 (Predicted)
Refractive Index :
n20D 1.60 (Predicted)
IC50 :
HL-60: IC50 = 1.3 µM (human); KB: IC50 = 3.38 µM (human); MH60: IC50 = 26.01 µM (mouse); HepG2: IC50 >50 µM (human)
pK Values :
pKa: 15.14
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
EI2975000
PubChem CID :
10063
Merck Index :
14: 8146
MDL Number :
MFCD00210361
SMILES :
CC12CCC(CC1CCC3C2CCC4(C35C(O5)CC4C6=COC(=O)C=C6)C)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Resibufogenin  Product Citations

See how others have used Resibufogenin. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 24390736  Wang, Y. et al. 2014. Cancer Res. 74: 1506-17.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 207ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Vu et al Vu et al. (PubMed ID 16446498) found that Resibufogenin reduced blood pressure to normal in rats with induced preeclampsia by inhibiting Na/K ATPase. -SCBT Publication Review
Date published: 2015-05-28
  • y_2019, m_11, d_12, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202788, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 106ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.